No Detail Found!

Efficacy of first available direct-acting antiviral agent in treatment of chronic hepatitis c; results from a single centre in Pakistan

Author(s)
Arif Qayyum Khan Combined Military Hospital Lahore/CMH Lahore Medical College and IOD/National University of Medical Sciences (NUMS), Pakistan
Hala Mansoor Combined Military Hospital Lahore/CMH Lahore Medical College and IOD/National University of Medical Sciences (NUMS), Pakistan
Javed Iqbal Combined Military Hospital Lahore/CMH Lahore Medical College and IOD/National University of Medical Sciences (NUMS), Pakistan
Raja Yasser Shahbaz Combined Military Hospital Lahore/CMH Lahore Medical College and IOD/National University of Medical Sciences (NUMS), Pakistan
Samina Fida Combined Military Hospital Lahore/CMH Lahore Medical College and IOD/National University of Medical Sciences (NUMS), Pakistan
Muhammad Siddique Combined Military Hospital Lahore/CMH Lahore Medical College and IOD/National University of Medical Sciences (NUMS), Pakistan
Abstract
Objective: To determine the efficacy of dual (sofosbuvir and ribavirin) and triple therapy (sofosbuvir-ribavirinpegylated interferon) for treatment of hepatitis C. Study Design: Comparative cross sectional study. Place and Duration of Study: Department of Medicine, Combined Military Hospital, Lahore, from Nov 2014 to Mar 2017. Methodology: A total of 182 consecutive patients with age =18 years and positive HCV RNA by polymerase chain reaction were included, while patients with haemoglobin of <10 g/dl, albumin <2 g/dl, platelet count of <100/uL, creatinine clearance of <60 mL/min or liver disease caused by non-hepatitis C related causes were excluded from study. Results: Total 129 (70.8%) were treated with dual and 53 (29.1%) with triple therapy. Amongst patients with genotype 3 (158/182), the overall sustained virological response at 12 weeks (SVR 12) was 94.4% in patients with dual therapy while it was 97.3% with triple therapy. In non-cirrhotic patients it was 95% in treatment naïve and 100% in treatment experienced group. While in cirrhotic patients with genotype 3, SVR 12 with dual therapy was 83.3% (p=0.331) and 88.9% in treatment naïve and treatment experienced patients respectively, while it was 100% in both groups with triple therapy. SVR 12 for genotype 1 (21/182) was 100%, both for dual as well as for triple therapy. Haematological side effects dominated the clinical picture with 11.5% suffering from anaemia. Conclusion: Both dual and triple therapy were effective in patients with hepatitis C with acceptable level of side effects, genotype 3 being the most predominant genotype.
Publication Details
Page(s) 1885-1891
DOI DOI not available
Published Journal: Pakistan Armed Forces Medical Journal, Volume: 70, Issue: 6, Year: 2020

Request the full text from PASTIC

Keywords
Hepatitis C virus (HCV), SVR 12.
0

Citations

0

Downloads

122

Views